New Patch for ADHD

Shire announced that its Attention Deficit Hyperactivity Disorder (ADHD) patch DAYTRANA is effective in patients converted to the patch from doses of their previous oral long-acting methylphenidate. This phase of clinical trial results were reported October 27, 2006 at a major scientific and educational meeting of child and adolescent psychiatrists in San Diego, Calif.

Two additional analyses presented at the meeting also demonstrated positive results with DAYTRANA. One analysis documented that treatment with the ADHD did not worsen ADHD-related sleep onset, sleep anxiety, or daytime sleepiness while another analysis evaluated validated parent satisfaction measures, considering both the efficacy and tolerability of the ADHD patch.

DAYTRANA, the first and only ADHD patch, is available in four dosage strengths - 10 mg, 15 mg, 20 mg and 30 mg - all designed for once-daily use. (Health News)